相似文献
1
What Have We Learned About Its Mechanisms of Pathogenicity?
Front Microbiol. 2018 Dec 12;9:3081. doi: 10.3389/fmicb.2018.03081. eCollection 2018.
2
Attack, Defend and Persist: How the Fungal Pathogen Candida auris was Able to Emerge Globally in Healthcare Environments.
Mycopathologia. 2019 Jun;184(3):353-365. doi: 10.1007/s11046-019-00351-w. Epub 2019 Jun 17.
3
Candida auris: an Emerging Fungal Pathogen.
J Clin Microbiol. 2018 Jan 24;56(2). doi: 10.1128/JCM.01588-17. Print 2018 Feb.
4
Characterization of the Differential Pathogenicity of Candida auris in a Galleria mellonella Infection Model.
Microbiol Spectr. 2021 Sep 3;9(1):e0001321. doi: 10.1128/Spectrum.00013-21. Epub 2021 Jun 9.
5
Candida auris Phenotypic Heterogeneity Determines Pathogenicity .
mSphere. 2020 Jun 24;5(3):e00371-20. doi: 10.1128/mSphere.00371-20.
6
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02396-16. Print 2017 May.
7
Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species.
mSphere. 2016 Aug 18;1(4). doi: 10.1128/mSphere.00189-16. eCollection 2016 Jul-Aug.
8
The Hog1 MAP kinase is essential for the colonization of murine skin and intradermal persistence.
mBio. 2024 Nov 13;15(11):e0274824. doi: 10.1128/mbio.02748-24. Epub 2024 Oct 18.
9
Mechanisms of pathogenicity for the emerging fungus Candida auris.
PLoS Pathog. 2023 Dec 21;19(12):e1011843. doi: 10.1371/journal.ppat.1011843. eCollection 2023 Dec.
10
Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface.
J Clin Microbiol. 2017 Oct;55(10):2996-3005. doi: 10.1128/JCM.00921-17. Epub 2017 Jul 26.
引用本文的文献
1
Epidemiological and microbiological characterization of Candidozyma auris (Candida auris) isolates from a tertiary hospital in Cairo, Egypt: an 18-month study.
Sci Rep. 2025 Sep 12;15(1):32427. doi: 10.1038/s41598-025-15302-3.
2
Geographical variation in the clinical profile of patients with .
Antimicrob Steward Healthc Epidemiol. 2025 Jul 28;5(1):e163. doi: 10.1017/ash.2025.10064. eCollection 2025.
3
and activity of sodium houttuyfonate and sodium new houttuyfonate against infection by affecting adhesion, aggregation, and biofilm formation abilities.
Microbiol Spectr. 2025 Jun 18:e0022225. doi: 10.1128/spectrum.00222-25.
4
Multidrug-Resistant and its Role in Carcinogenesis: A Scoping Review.
Malays J Med Sci. 2025 Feb;32(1):6-15. doi: 10.21315/mjms-09-2024-691. Epub 2025 Feb 28.
5
Synergistic Antifungal Activity of Pentamidine and Auranofin Against Multidrug-Resistant Candida auris.
Mycopathologia. 2025 May 14;190(3):41. doi: 10.1007/s11046-025-00948-4.
6
Emergence and characterization of mixed Candida auris strain infections in China.
Infection. 2025 Apr 14. doi: 10.1007/s15010-025-02536-6.
7
Comparative evaluation of biologically and chemically synthesized zinc oxide nanoparticles for preventing Candida auris biofilm.
Biometals. 2025 Mar 31. doi: 10.1007/s10534-025-00678-6.
8
Exploring the Potential of sp. SW4-6 as a Probiotic for Enhancing Water Quality in Aquaculture.
Microorganisms. 2024 Dec 29;13(1):42. doi: 10.3390/microorganisms13010042.
9
Nanoparticles in the battle against Candida auris biofilms: current advances and future prospects.
Drug Deliv Transl Res. 2025 May;15(5):1496-1512. doi: 10.1007/s13346-024-01749-w. Epub 2024 Nov 26.
10
Regulation of oxidative stress enzymes in by Dermaseptin: potential implications for antifungal drug discovery.
RSC Adv. 2024 Nov 20;14(49):36886-36894. doi: 10.1039/d4ra06392a. eCollection 2024 Nov 11.
本文引用的文献
1
Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species.
Nat Commun. 2018 Dec 17;9(1):5346. doi: 10.1038/s41467-018-07779-6.
2
Emerging Fungal Pathogen Candida auris Evades Neutrophil Attack.
mBio. 2018 Aug 21;9(4):e01403-18. doi: 10.1128/mBio.01403-18.
3
Transcriptome Assembly and Profiling of Reveals Novel Insights into Biofilm-Mediated Resistance.
mSphere. 2018 Jul 11;3(4):e00334-18. doi: 10.1128/mSphere.00334-18.
4
The first isolate of Candida auris in China: clinical and biological aspects.
Emerg Microbes Infect. 2018 May 18;7(1):93. doi: 10.1038/s41426-018-0095-0.
5
Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model.
Mycoses. 2018 Jun;61(6):377-382. doi: 10.1111/myc.12754. Epub 2018 Mar 14.
6
Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface.
J Clin Microbiol. 2017 Oct;55(10):2996-3005. doi: 10.1128/JCM.00921-17. Epub 2017 Jul 26.
7
Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species.
Infect Control Hosp Epidemiol. 2017 Sep;38(9):1107-1109. doi: 10.1017/ice.2017.127. Epub 2017 Jul 11.
8
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02396-16. Print 2017 May.
9
Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris.
Emerg Infect Dis. 2017 Feb;23(2):328-331. doi: 10.3201/eid2302.161320.
10
Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel.
Emerg Infect Dis. 2017 Feb;23(1):195-203. doi: 10.3201/eid2302.161486.
Zotero 插件